Vasculitis News and Research

RSS
Vasculitis is a condition that involves inflammation in the blood vessels. The condition occurs if your immune system attacks your blood vessels by mistake. This may happen as the result of an infection, a medicine, or another disease or condition. The inflammation can lead to serious problems. Complications depend on which blood vessels, organs, or other body systems are affected. Vasculitis can affect any of the body's blood vessels. These include arteries, veins, and capillaries. Arteries carry blood from your heart to your body's organs. Veins carry blood from your organs and limbs back to your heart. Capillaries connect the small arteries and veins.
Survey says half of people with rheumatoid disease struggle to pay for treatment

Survey says half of people with rheumatoid disease struggle to pay for treatment

Tiny fat bubbles hold key to rebooting the immune system and calming disease process

Tiny fat bubbles hold key to rebooting the immune system and calming disease process

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Promising methods for early detection and treatment of rheumatoid arthritis

Promising methods for early detection and treatment of rheumatoid arthritis

Radiation-induced vascular damage could be treated with IL-1 inhibitors

Radiation-induced vascular damage could be treated with IL-1 inhibitors

Association found between gene variant and lung disease in the form of systemic vasculitis

Association found between gene variant and lung disease in the form of systemic vasculitis

Researchers reveal promising biomarker for vascular disease relapse

Researchers reveal promising biomarker for vascular disease relapse

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Meta-analysis reveals effective treatment options for urticarial vasculitis

Meta-analysis reveals effective treatment options for urticarial vasculitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Health Care Apps and the Empowered Patient

Health Care Apps and the Empowered Patient

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer announces FDA approval of biosimilar to Neupogen

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis

Study: Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis